Bibliography
- MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912-1934.
- KLEBL BM, MILLER G: Second-generation kinase inhibitors. Expert Opin. Ther. Targets (2005) 9(5):975-993.
- COOPER CS, PARK M, BLAIR DG et al.: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 311:29-33.
- PARK M, DEAN M, COOPER CS et al.: Mechanism of Met oncogene activation. Cell (1986) 45:895-904.
- MAULIK G, SHRIKHANDE A, KIJIMA T, MA PC, MORRISON PT, SALGIA R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. (2002) 13:41-59.
- MA PC, MAULIK G, CHRISTENSEN J, SALGIA R: c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. (2003) 22:309-325.
- JEFFERS M, SCHMIDT L, NAKAIGAWA N et al.: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA (1997) 94:11445-11450.
- OTSUKA T, JAKUBCZAK J, VIEIRA W et al.: Disassociation of Met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol. Cell Biol. (2000) 20:2055-2065.
- MATSUMOTO K, NAKAMURA T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Gann Monogr. Cancer Res. (2004) 52:125-139.
- BURGESS T, COXON A, MEYER S et al.: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met–dependent human tumors. Cancer Res. (2006) 66(3):1721-1729.
- BARDELLI A, LONGATI P, WILLIAMS TA, BENVENUTI S, COMOGLIO PM: A peptide representing the carboxyl-terminal tail of the Met receptor inhibits kinase activity and invasive growth. J. Biol. Chem. (1999) 274:29274-29281.
- MOROTTI A, MILA S, ACCORNERO P, TAGLIABUE E, PONZETTO C: K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene (2002) 20:1692-1703.
- CHRISTENSEN JG, SCHRECK R, BURROWS J et al.: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antimutor activity in vivo. Cancer Res. (2003) 63(21):7345-7355.
- HOV H, UTNE HOLT R, BAADE RØ T et al.: A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhension of myeloma cells. Clin. Cancer Res. (2004) 10(10):6686-6694.
- LURUSSO P, APPLEMAN L, HEATH E et al.: A Phase I study of a novel spectrum kinase inhibitor (SSKI), XL-880, administrated orally in patients with solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, USA (14-18 November, 2005) A245.
Patents
- PFIZER: WO2004076412 (2004).
- PFIZER: WO2005004607 (2005).
- PFIZER: WO2005004808 (2005).
- PFIZER: WO2005005378 (2005).
- PFIZER: WO2005121125 (2005).
- VERTEX: WO2005016920 (2005).
- VERTEX: WO2005040345 (2005).
- KIRIN: WO03000660 (2003).
- AMGEN: WO2005017107 (2005).
- AMGEN: WO2005070891 (2005).
- AMGEN: WO2005073224 (2005).
- EISAI: WO2005082855 (2005).
- EISAI: WO2005082854 (2005).
- BRISTOL-MYERS SQUIBB: WO2005116028 (2005).
- BRISTOL-MYERS SQUIBB: WO2005117867 (2005).
- EXELIXIS: WO2005030140 (2005).
- EXELIXIS: WO2005014325 (2005).